Suzanne Hodgkinson - Concepedia

Author

Suzanne Hodgkinson

Also Known As

Abdullah Al-Asmi, Anneke van der Walt, Bruce Taylor, Freek Verheul, Hodgkinson, S, J. Grundy, M. Lai, Michael Barnett, Michael D. Dreyer, S Hodgkinson

270

Publications

8.1K

Citations

H-Index

105

Concepts

All Affiliations

Liverpool Hospital UNSW Sydney The University of Melbourne The Royal Melbourne Hospital Monash University

About

Suzanne Hodgkinson is an author at Liverpool Hospital specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	2.9K
2	Public Health	3	3	104
3	Health Sciences	2	2	1.3K
4	Engineering	1	1	12
5	Social Sciences	1	1	12

Suzanne Hodgkinson

105

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis D. H. Miller, Paul S. Albert, Frederik Barkhof, Annals of Neurology	1996	444
C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy Anna Richards, Arn M. J. M. van den Maagdenberg, Joanna C. Jen, Nature Genetics Ocular DiseaseC-terminal TruncationsRetinaOphthalmologyGenetic Disorder	2007	444
Defining secondary progressive multiple sclerosis Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Brain Neurological DisorderDisabilityClinical NeurologyNeurological ProgressNeurological Rehabilitation	2016	401
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial Bob W. van Oosten, Mitchell K.P. Lai, Suzanne Hodgkinson, Neurology	1997	265
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis Vilija Jokubaitis, Tim Spelman, Tomáš Kalinčík, Annals of Neurology	2016	192
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations Anine H Stam, Parul H. Kothari, Aisha Shaikh, Brain	2016	167
A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Dawn E. Smilek, David C. Wraith, Suzanne Hodgkinson, Proceedings of the National Academy of Sciences ImmunologyImmune RegulationImmunologic MechanismImmunotherapyNeuroinflammation	1991	165
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis Tomáš Kalinčík, Dana Horáková, Tim Spelman, Annals of Neurology	2014	157
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study Tomáš Kalinčík, J William L Brown, Neil P. Robertson, The Lancet Neurology Disease ProgressionMedicineSystemic TreatmentImmunologyClinical Trials	2017	157

Page 1